Latest Advisory

2018 Operational Planning of the Center for Food Regulation Research

Please be informed that the Center For Food Regulation Research will conduct its 2018 Operational Planning on 17-19 December 2018 which will be held within Bataan.

All transactions will be entertained until 14 December 2018 and will resume on 20 December 2018.


Press Statement
10 December 2018 

The FDA, through its inspectors at the Regional Field Offices (RFO) and agents of its Regulatory Enforcement Unit (REU), in coordination with the Philippine National Police (with whom the FDA has an existing MOA), is continuously monitoring the sale of the unregistered alcoholic beverage, Lambanog, and will not hesitate to confiscate these products being openly sold to the public, to prevent further loss of life to unsuspecting consumers.  The FDA issued an Order for the seizure of these unregistered products, and the RFO inspectors and REU agents are on heightened alert status to make sure that none of these toxic alcoholic beverages are marketed in the public.   

This is in line with its recent findings that laboratory tests of the sample products from Luisiana, Sta. Rosa and Calamba, Laguna, Antipolo, and Tarlac, which tested positive for high levels of Methanol, a prohibited additive in Lambanog, and which is suspected to have caused the deaths of some individuals.   

FDA is also monitoring other Lambanog products in the market as part of its heightened Post Marketing Surveillance (PMS), which are being immediately subjected to product registration verification, and qualitative and quantitative analysis by its Common Services Laboratory (CSL), to prevent further injury and loss of life. 

FDA will be filing cases against the identified peddlers of these unregistered, out of specs, and/or adulterated alcoholic beverages, and will be coordinating with other law enforcement services, for the filing of the appropriate criminal cases against the perpetrators – especially those involved or connected with the deaths allegedly caused by these unregistered products.  

The Center for Drug Regulation and Research (CDRR) will be closed on 22-23 November 2018 (Thursday and Friday) to give way for the 2018 Echo-Seminar on Local and International Training on the Quality, Efficacy and Safety Drugs.

Regular transactions will resume on 26 November 2018 (Monday).

For any inquiries, please send e-mail to: This email address is being protected from spambots. You need JavaScript enabled to view it. or This email address is being protected from spambots. You need JavaScript enabled to view it.

FDA Advisory No. 2018-325

Public Health Warning on the sale/consumption of alcoholic beverage, Lambanog, that are not registered with the Food and Drug Administration

The Food and Drug Administration (FDA) received information that multiple deaths have occurred purportedly resulting fro the consumption of the alcoholic beverage, Lambanog

The FDA, in coordination with the Department of Health - Epidemiology Bureau and the concerned local government units, immediately secured samples of these product verification and laboratory analysis, and have confirmed that they are NOT registered, and contain high levels of the substance "Methanol".

Products that are not registered with the FDA pose potential health hazards to the consuming public since they have not gone through the agency's evaluation and testing. Thus, the FDA cannot guarantee their quality and safety.

Ingestion of products with high amounts of Methanol poses adverse effects like blindness and permanent neurologic dysfunction, among others, and may even lead to death.

The public is advised to exercise extreme caution in purchasing/consuming the alcohol beverage, Lambanog, and is advised to only purchase/consume those which are registered with thw FDA.

Please be informed that the conduct of Unified Licensing Seminar for Region IV-B (Course Code: ULS-IV-B) scheduled on 23 November 2018 in Puerto Princesa City shall be postponed due to very low number of course participants that registered in the course.

Rest assured that all changes and concerns of the registered participants of this seminar shall be attended to by the FDA Academy staff. For more information and update regarding this seminar, please visit the FDA website, Please be guided accordingly.

For inquiries and other concerns, you may reach the FDA Academy thru:

  • Telephone Number: (02) 877 0259
  • Email Address: This email address is being protected from spambots. You need JavaScript enabled to view it. or This email address is being protected from spambots. You need JavaScript enabled to view it.

Share Us on

Submit to FacebookSubmit to Google PlusSubmit to Twitter